StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) stock

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Earnings

Abbott Laboratories's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Jan 21, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$13.01B
+14.5% on a year earlier
adjusted diluted EPS, Q3 FY2026
$1.42
$1.30 a year earlier
Latest guidance
Issued
Oct 21, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Abbott Laboratories's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Jan 21, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 21, 2026before the open$13.01B+14.5%$0.53$1.42Release
Q2 FY2026ended Jun 30, 2026Jul 16, 2026before the open$12.59B+13.0%$0.53$1.31Release
Q1 FY2026ended Mar 31, 2026Apr 16, 2026before the open$11.16B+7.8%$0.61$1.15Release
Q4 FY2025ended Dec 31, 2025Jan 22, 2026before the open$11.46B+4.2%$1.01$1.50Release
Q3 FY2025ended Sep 30, 2025Oct 15, 2025before the open$11.37B+7.3%$0.94$1.30Release
Q2 FY2025ended Jun 30, 2025Jul 17, 2025before the open$11.14B+7.1%$1.01$1.26Release
Q1 FY2025ended Mar 31, 2025Apr 16, 2025before the open$10.36B+3.6%$0.76$1.09Release
Q4 FY2024ended Dec 31, 2024Jan 22, 2025before the open$11.00B+7.4%$5.27$1.34Release
Q3 FY2024ended Sep 30, 2024Oct 16, 2024before the open$10.60B+5.0%$0.94$1.21Release
Q2 FY2024ended Jun 30, 2024Jul 18, 2024before the open$10.40B+4.0%$0.74$1.14Release
Q1 FY2024ended Mar 31, 2024Apr 17, 2024before the open$10.00B+3.1%$0.70$0.98Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Abbott Laboratories's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
adjusted diluted earnings per sharenon-GAAPQ4 FY2026$1.62 – $1.67–NewOct 21, 2026
organic sales growthnon-GAAPFY2026+6.5% – +7.5%–NewJan 22, 2026
comparable sales growthnon-GAAPFY2026+6%–NewOct 21, 2026
comparable sales growthnon-GAAPFY2026+6.5% – +7.5%+6.5% – +7.5%ReaffirmedJul 16, 2026
adjusted diluted earnings per sharenon-GAAPFY2026$5.50 – $5.55–NewOct 21, 2026
adjusted diluted earnings per sharenon-GAAPFY2026$5.45 – $5.60$5.38 – $5.58RaisedJul 16, 2026

Guidance vs results

The last range Abbott Laboratories gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026adjusted diluted earnings per share$1.38 – $1.46$1.42Within range
Q2 FY2026adjusted diluted earnings per share$1.25 – $1.31$1.31Within range
Q1 FY2026adjusted diluted earnings per share$1.12 – $1.18$1.15Within range
FY2025adjusted diluted EPS guidance$5.12 – $5.18$5.15Σ4QWithin range
Q3 FY2025adjusted diluted earnings per share$1.28 – $1.32$1.30Within range
Q2 FY2025adjusted diluted earnings per share$1.23 – $1.27$1.26Within range
Q1 FY2025adjusted diluted earnings per share$1.05 – $1.09$1.09Within range
Q4 FY2024EPS (GAAP)$0.96 – $1.02$5.27Above range
Q4 FY2024projected adjusted diluted earnings per share$1.31 – $1.37$1.34Within range
Q3 FY2024adjusted diluted earnings per share$1.18 – $1.22$1.21Within range
Q3 FY2024EPS (GAAP)$0.85 – $0.89$0.94Above range
Q2 FY2024EPS (GAAP)$0.69 – $0.73$0.74Above range

Guidance history

Every forecast Abbott Laboratories put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 21, 2026comparable sales growthFY2026+6%New
Oct 21, 2026adjusted diluted earnings per shareQ4 FY2026$1.62 – $1.67New
Oct 21, 2026adjusted diluted earnings per shareFY2026$5.50 – $5.55New
Jul 16, 2026comparable sales growthFY2026+6.5% – +7.5%Reaffirmed
Jul 16, 2026adjusted diluted earnings per shareQ3 FY2026$1.38 – $1.46New
Jul 16, 2026adjusted diluted earnings per shareFY2026$5.45 – $5.60Raised
Apr 16, 2026comparable sales growthFY2026+6.5% – +7.5%New
Apr 16, 2026adjusted diluted earnings per shareFY2026$5.38 – $5.58Lowered
Apr 16, 2026adjusted diluted earnings per shareQ2 FY2026$1.25 – $1.31New
Jan 22, 2026adjusted diluted earnings per shareQ1 FY2026$1.12 – $1.18New
Jan 22, 2026adjusted diluted earnings per shareFY2026$5.55 – $5.80New
Jan 22, 2026organic sales growthFY2026+6.5% – +7.5%New
Oct 15, 2025adjusted diluted EPS guidanceFY2025$5.12 – $5.18Narrowed
Oct 15, 2025organic sales growth guidance, when including COVID-19 testing-related salesFY2025+6% – +7%Lowered
Oct 15, 2025organic sales growth guidance, excluding COVID-19 testing-related salesFY2025+7.5% – +8%New
Jul 17, 2025adjusted diluted earnings per shareQ3 FY2025$1.28 – $1.32New
Jul 17, 2025adjusted diluted earnings per shareFY2025$5.10 – $5.20New
Jul 17, 2025adjusted operating marginFY202523.5%New
Jul 17, 2025organic sales growth, excluding COVID-19 testing related salesFY2025+7.5% – +8%New
Jul 17, 2025organic sales growth when including COVID-19 testing-related salesFY2025+6% – +7%Lowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Abbott Laboratories filed with the SEC as exhibits to Form 8-K or 6-K

  1. Abbott announces its intention to separate
    News
  2. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
    Results
  3. Abbott reaches agreements to resolve
    Update
  4. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
    Results
  5. IN THE UNITED STATES DISTRICT COURT
    News
  6. Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
    Results
  7. Abbott completes acquisition of Exact
    News
  8. Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
    Results
  9. to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
    Update
  10. Acquisition of Exact Sciences 20 | November | 2025
    Update
  11. Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance
    Results
  12. Abbott Reports Second-Quarter 2025 Results
    Results
  13. Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance
    Results
  14. Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook
    Results
  15. Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range
    Results